

## COMMONWEALTH OF KENTUCKY

FAYETTE CIRCUIT COURT  
DIVISION III

CIVIL ACTION NO. 18-CI-3762

*Electronically Filed*COMMONWEALTH OF KENTUCKY, *ex rel.*,  
DANIEL CAMERON, ATTORNEY GENERAL,

PLAINTIFF

v.

TEVA PHARMACEUTICAL INDUSTRIES, LTD., *et al.*

DEFENDANTS

**COVER SHEET TO  
FINAL CONSENT JUDGMENT AND DISMISSAL WITH PREJUDICE**


The Final Consent Judgment and Dismissal with Prejudice attached hereto has been agreed to by the Commonwealth of Kentucky, ex. rel. Daniel Cameron, Attorney General, and Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn was f/k/a Watson Pharmaceuticals, Inc.), Allergan Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc), Allergan Sales LLC, and Allergan USA, Inc. (collectively, “Allergan” or “Defendants”). The Commonwealth and Allergan request that the Court enter the attached Final Consent Judgment and Dismissal with Prejudice.

In relation to the filing of the Final Consent Judgment and Dismissal with Prejudice in the applicable court in the Commonwealth of Kentucky as required by statute, Allergan waives notice and service of process regarding the filing of the Final Consent Judgment and Dismissal with Prejudice and does not object to the court’s approval and entry of the Final Consent Judgment and

Dismissal with Prejudice. Allergan also does not object to the submission and presentation of this Final Consent Judgment and Dismissal with Prejudice by the Kentucky Attorney General’s Office to the court.

WHEREFORE, the Court being well and sufficiently advised in the premises, and the Court having jurisdiction and venue for the purposes of entering and enforcing this judgment, the Final Consent Judgment and Dismissal with Prejudice attached hereto is hereby approved and the above referenced Civil Action is dismissed with prejudice.

The Office of the Attorney General shall receive fifteen percent (15%) of each payment referenced in KRS 15.293(3)(a) as its reasonable costs of investigation and litigation per KRS 48.005.



---

Lucy VanMeter, Judge  
Fayette Circuit Court, Division 3

## COMMONWEALTH OF KENTUCKY

FAYETTE CIRCUIT COURT  
DIVISION III

CIVIL ACTION NO. 18-CI-3762

*Electronically Filed*COMMONWEALTH OF KENTUCKY, *ex rel.*,  
DANIEL CAMERON, ATTORNEY GENERAL,

PLAINTIFF

v.

TEVA PHARMACEUTICAL INDUSTRIES, LTD., *et al.*

DEFENDANTS

**FINAL CONSENT JUDGMENT AND DISMISSAL WITH PREJUDICE**

The Commonwealth of Kentucky, *ex rel.*, Daniel Cameron, Attorney General (“Commonwealth”) and Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn was f/k/a Watson Pharmaceuticals, Inc.), Allergan Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc), Allergan Sales LLC, and Allergan USA, Inc. (collectively, “*Allergan*” or “*Defendants*”) (together with the Commonwealth, the “*Parties*,” and each a “*Party*”) have entered into a consensual resolution of the above-captioned litigation (the “*Action*”), pursuant to a settlement agreement entitled Allergan Public Global Opioid Settlement Agreement, dated as of November 22, 2022 (as subsequently updated) (the “*Agreement*”), a copy of which is attached hereto as Exhibit A. The Agreement shall become effective by its terms upon the entry of this Final Consent Judgment (the “*Judgment*”) by the Court without trial or adjudication of any contested issue of fact or law, and without finding or admission of wrongdoing or liability of any

kind. This Consent Judgment resolves litigation as to “Allergan” and the “Released Entities” as those terms are defined in the Allergan Public Global Opioid Settlement Agreement.

**RECITALS:**

1. Each Party warrants and represents that it engaged in arm’s-length negotiations in good faith. By entering into the Agreement, the Parties intended to effect a good-faith settlement.

2. The Commonwealth has determined that the Agreement is in the public interest.

3. Allergan denies the allegations in the Action and maintains that it has no liability whatsoever to the Commonwealth, its Subdivisions, its Special Districts and/or any other governmental entity (whether or not such governmental entity has brought or is a party to an Action or not).

4. The Parties have agreed to the resolution of the Action and the entry of this Judgment (including the injunctive terms incorporated herein) by the Court without trial or finding of admission or wrongdoing or liability of any kind.

5. The Parties recognize that the outcome of the Action is uncertain and a final resolution through the adversarial process likely will require protracted litigation.

6. Allergan is entering into this Judgment solely for the purpose of settlement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, regulation, or ordinance, or of any other matter of fact or law, or of any fault, liability, or wrongdoing, all of which Allergan denies.

7. The Parties agree to the entry of the injunctive relief terms pursuant to Exhibit P of the Agreement.

8. Therefore, without any admission of liability or wrongdoing by Allergan or any other Released Entities (as defined in the Agreement), the Parties now mutually consent to the

entry of this Judgment and agree to dismissal of the claims with prejudice pursuant to the terms of the Agreement to avoid the delay, expense, inconvenience, and uncertainty of protracted litigation.

**NOW THEREFORE, IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:**

In consideration of the mutual promises, terms, and conditions set forth in the Agreement, the adequacy of which is hereby acknowledged by all Parties, it is agreed by and between Defendants and the Commonwealth, and adjudicated by the Court, as follows:

1. The foregoing Recitals are incorporated herein and constitute an express term of this Judgment.

2. The Parties have entered into a full and final settlement of all Released Claims of Releasers (including but not limited to the Commonwealth) against Allergan and the Released Entities pursuant to the terms and conditions set forth in the Agreement.

3. The “Definitions” set forth in Section I of the Agreement are incorporated by reference into this Judgment. The Commonwealth is a “Settling State” within the meaning of the Agreement. Unless otherwise defined herein, capitalized terms in this Judgment shall have the same meaning given to them in the Agreement. In the event of a conflict between the terms of the Agreement and this summary document, the terms of the Agreement shall govern.

4. The Parties agree that the Court has jurisdiction over the subject matter of the Action and over the Parties with respect to the Action and this Judgment. This Judgment shall not be construed or used as a waiver of any jurisdictional defense Allergan or any other Released Entity may raise in any other proceeding.

5. The Court finds that the Agreement was entered into in good faith.

6. The Court finds that entry of this Judgment is in the public interest and reflects a negotiated settlement agreed to by the Parties. The Action is dismissed with prejudice, subject to a retention of jurisdiction by the Court as provided herein and in the Agreement.

7. By this Judgment, the Agreement is hereby approved by the Court, and the Court hereby adopts the Agreement's terms as its own determination of this matter and the Parties' respective rights and obligations.

8. The Court shall have authority to resolve disputes identified in Section XIV.G.2 of the Agreement, governed by the rules and procedures of the Court.

9. The Parties have satisfied the Condition to Effectiveness of Agreement set forth in Section X of the Agreement and the Release set forth in Sections V.A, E and F of the Agreement, as follows:

- a. The Attorney General of the State exercised the fullest extent of his or her powers to release Allergan and all other Released Entities from all Released Claims pursuant to the release attached hereto as Exhibit B (the "*Release*").
- b. Allergan has determined that there is sufficient State participation and sufficient resolution of the actual and potential Claims of the Subdivisions and Special Districts in the Settling States to proceed with the Agreement.
- c. The Settlement Participation Form for each Initial Participating Subdivision and Initial Participating Special District in the State has been delivered to Allergan. As stated in the Settlement Participation Form, and for the avoidance of doubt, nothing in the Settlement Participation Form executed by the Participating Subdivisions or Participating Special Districts is intended to modify in any way the terms of the Agreement to which the Participating Subdivisions and Participating Special Districts agree. As stated in the Settlement Participation Form, to the extent the executed version of the Settlement Participation Form differs from the Agreement in any respect, the Agreement controls.
- d. Pursuant to the Settlement Participation Form, each Participating Subdivision and Participating Special District in the State is dismissing with prejudice any Released Claims that it has filed against Allergan and the Released Entities.

10. Release. The Parties acknowledge that the Release, which is incorporated by reference herein, is an integral part of this Judgment. Pursuant to the Agreement and the Release and without limitation and to the maximum extent of the power of the Commonwealth's Attorney General, Allergan and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (a) the Commonwealth and its Participating Subdivisions and

Participating Special Districts and any of their departments, agencies, divisions, boards, commissions, Subdivisions, districts, instrumentalities of any kind and attorneys, including the Commonwealth's Attorney General, and any person in their official capacity whether elected or appointed to serve any of the foregoing, and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, water districts, emergency services districts, school districts, healthcare districts, hospital districts, Sheriffs and law enforcement districts, library districts, coroner's offices, and public transportation authorities and other Special Districts in the Commonwealth, including those with the regulatory authority to enforce state and federal controlled substances acts or the authority to bring Claims related to Covered Conduct seeking money (including abatement (or remediation and/or restitution)) or revoke a pharmaceutical distribution license, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief, including but not limited to, fines, penalties, or punitive damages, on behalf of or generally applicable to the general public with respect to the Commonwealth or any Subdivision or Special District in the Commonwealth, whether or not any of them participate in the Agreement. Pursuant to the Agreement and the Release and to the maximum extent of the Commonwealth's power, Allergan and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (1) the Commonwealth, (2) all past and present executive departments, state agencies, divisions, boards, commissions and instrumentalities with the regulatory authority to enforce state and federal controlled substances acts, (3) any of the Commonwealth's past and present executive departments, agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Covered

Conduct seeking money (including abatement and/or remediation) or revocation of a pharmaceutical distribution license, and (4) any Participating Subdivision or Participating Special District. For the purposes of clause (3) above, executive departments, agencies, divisions, boards, commissions, and instrumentalities are those that are under the executive authority or direct control of the Commonwealth's Governor. Further, the provisions set forth in Section V of the Agreement are incorporated by reference into this Judgment as if fully set forth herein. The Parties acknowledge, and the Court finds, that those provisions are an integral part of the Agreement and this Judgment and shall govern the rights and obligations of all participants in the settlement. Any modification of those rights and obligations may be made based only on a writing signed by all affected parties and approved by the Court.

11. Release of Unknown Claims. The Commonwealth expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

**General Release; extent.** A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

12. The Commonwealth may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but the Commonwealth expressly waived and fully, finally, and forever settled, released and discharged, through the Agreement and Release, any and all Released Claims that may exist as of the Effective Date but which the Commonwealth does not know or suspect to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and which, if known, would have materially affected the Commonwealth's decision to enter into the Agreement.



13. Costs and Fees. The Parties will bear their own costs and attorneys' fees except as otherwise provided in the Agreement.

14. No Admission of Liability. Defendants are consenting to this Judgment solely for the purpose of effectuating the Agreement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or wrongdoing, all of which Defendants expressly deny. No Defendant or Released Entity admits that it caused or contributed to any public nuisance, and no Defendant or Released Entity admits any wrongdoing that was or could have been alleged by the Commonwealth, its Participating Subdivisions and/or Participating Special Districts, or any other person or entity. No part of this Judgment shall constitute evidence of any liability, fault, or wrongdoing by Defendants or any other Released Entity. The Parties acknowledge that payments made under the Agreement are not a fine, penalty, or payment in lieu thereof and are properly characterized as described in Section VIII.G of the Agreement.

15. No Waiver. This Judgment is entered based on the Agreement without trial or adjudication of any contested issue of fact or law or finding of liability of any kind. This Judgment shall not be construed or used as a waiver of Allergan's right, or any other Released Entity's right, to defend itself from, or make any arguments in, any other regulatory, governmental, private individual, or class claims or suits relating to the subject matter or terms of this Judgment. Notwithstanding the foregoing, the Commonwealth may enforce the terms of this Judgment as expressly provided in the Agreement.

16. No Private Right of Action. No part of this Order or of the Agreement shall create a private cause of action or confer any right to any third party for violation of any federal or state statute. This Judgment is not intended for use by any third party for any purpose, including

submission to any court for any purpose, except pursuant to Section XIV.A of the Agreement. Except as expressly provided in the Agreement, no portion of the Agreement or this Judgment shall provide any rights to, or be enforceable by, any person or entity that is not a Settling State or Released Entity. The Commonwealth shall allow Participating Subdivisions and Participating Special Districts in the Commonwealth to notify it of any perceived violations of the Agreement or this Judgment. No Settling State, including the Commonwealth, may assign or otherwise convey any right to enforce any provision of the Agreement.

17. Admissibility. It is the intent of the Parties that this Judgment not be admissible in other cases against Defendants or Released Entities or binding on Defendants or Released Entities in any respect other than in connection with the enforcement of this Judgment or the Agreement. For the avoidance of doubt, nothing herein shall prohibit Defendants or Released Entities from entering this Judgment or the Agreement into evidence in any litigation or arbitration concerning (1) Defendants' or Released Entities' right to coverage under an insurance contract or (2) the enforcement of the releases provided for by the Agreement and this Judgment.

18. Preservation of Privilege. Nothing contained in the Agreement or this Judgment, and no act required to be performed pursuant to the Agreement or this Judgment, is intended to constitute, cause, or effect any waiver (in whole or in part) of any attorney-client privilege, work product protection, or common interest/joint defense privilege, and each Party agrees that it shall not make or cause to be made in any forum any assertion to the contrary.

19. Mutual Interpretation. The Parties agree and stipulate that the Agreement was negotiated on an arm's-length basis between parties of equal bargaining power and was drafted jointly by counsel for each Party. Accordingly, the Agreement is incorporated herein by reference

and shall be mutually interpreted and not construed in favor of or against any Party, except as expressly provided for in the Agreement.

20. Retention of Jurisdiction. The Court shall retain jurisdiction of the Parties for the limited purpose of the resolution of disputes identified in Section XIV.G.2 of the Agreement. The Court shall have jurisdiction over Participating Subdivisions and Participating Special Districts in the Commonwealth for the limited purposes identified in the Agreement.

21. Successors and Assigns. This Judgment is binding on Defendants’ successors and assigns.

22. Modification. This Judgment shall not be modified (by the Court, by any other court, or by any other means) without the consent of the Commonwealth and Defendants, or as provided for in Section XVI.T of the Agreement.

So ORDERED this \_\_\_\_ day of \_\_\_\_\_, 2023.

Enter:

By Order:



**APPROVED, AGREED TO AND PRESENTED BY:**

**TENDERED BY:**

/s/ J. Christian Lewis  
J. Christian Lewis  
Office of the Kentucky Attorney General  
700 Capital Avenue, Suite 118  
Frankfort, Kentucky 40601  
[christian.lewis@ky.gov](mailto:christian.lewis@ky.gov)

**HAVING SEEN AND AGREED:**/s/ Judd R. Uhl

Judd R. Uhl  
 Aimee E. Muller  
 Sebastian Torres  
 Lewis, Brisbois, Bisgaard & Smith  
 2333 Alexandria Drive  
 Lexington, KY 40503  
[judd.uhl@lewisbrisbois.com](mailto:judd.uhl@lewisbrisbois.com)  
[aimee.muller@lewisbrisbois.com](mailto:aimee.muller@lewisbrisbois.com)  
[sebastian.torres@lewisbrisbois.com](mailto:sebastian.torres@lewisbrisbois.com)

Jeffrey A. Kaplan, Jr.  
 Jennifer B. Flannery (admitted *pro hac vice*)  
 Sharnell S. Simon (admitted *pro hac vice*)  
 Jones Day  
 1221 Peachtree Street, N.E., Suite 400  
 Atlanta, GA 30361  
[jkaplan@jonesday.com](mailto:jkaplan@jonesday.com)  
[jbflannery@jonesday.com](mailto:jbflannery@jonesday.com)  
[sharnellsimon@jonesday.com](mailto:sharnellsimon@jonesday.com)

Rebecca Cauley Fitzpatrick (admitted *pro hac vice*)  
 300 N. LaSalle  
 Chicago, IL 60654  
[rebecca.fitzpatrick@kirkland.com](mailto:rebecca.fitzpatrick@kirkland.com)

*Counsel for Defendants Allergan plc; Allergan Finance, LLC; Allergan Sales LLC; and Allergan USA, Inc.*

/s/ J. Christian Lewis

Christopher Thacker  
 J. Christian Lewis  
 Stephen B. Humphress  
 Office of the Kentucky Attorney General  
 700 Capital Avenue, Suite 118  
 Frankfort, Kentucky 40601  
[christopher.thacker@ky.gov](mailto:christopher.thacker@ky.gov)  
[christian.lewis@ky.gov](mailto:christian.lewis@ky.gov)  
[steve.humphress@ky.gov](mailto:steve.humphress@ky.gov)

Mimi Liu (admitted *pro hac vice*)  
 Linda Singer (admitted *pro hac vice*)  
 Elizabeth Smith (admitted *pro hac vice*)  
 Brendan Austin (admitted *pro hac vice*)  
 David Ackerman (admitted *pro hac vice*)  
 David Burnett (admitted *pro hac vice*)  
 Motley Rice LLC  
 401 9<sup>th</sup> Street NW, Suite 1001  
 Washington, DC 20004  
[mliu@motleyrice.com](mailto:mliu@motleyrice.com)  
[lsinger@motleyrice.com](mailto:lsinger@motleyrice.com)  
[esmith@motleyrice.com](mailto:esmith@motleyrice.com)  
[baustin@motleyrice.com](mailto:baustin@motleyrice.com)  
[dackerman@motleyrice.com](mailto:dackerman@motleyrice.com)  
[dburnett@motleyrice.com](mailto:dburnett@motleyrice.com)

Fred C. Baker (admitted *pro hac vice*)  
 Christopher Moriarty (admitted *pro hac vice*)  
 Cindy Solomon (admitted *pro hac vice*)  
 Kristen Hermiz (admitted *pro hac vice*) Sarah Couch (admitted *pro hac vice*) Motley Rice LLC  
 28 Bridgeside Blvd.  
 Mount Pleasant, SC 29464  
[fbaker@motleyrice.com](mailto:fbaker@motleyrice.com)  
[cmoriarty@motleyrice.com](mailto:cmoriarty@motleyrice.com)  
[csolomon@motleyrice.com](mailto:csolomon@motleyrice.com)  
[khermiz@motleyrice.com](mailto:khermiz@motleyrice.com)  
[scouch@motleyrice.com](mailto:scouch@motleyrice.com)

*Counsel for Plaintiff Commonwealth of Kentucky*